Minimal residual disease (MRD) may be prevalent in clinical trials and discussed at conferences, but it is not really used widely in practice, said C. Ola Landgren, MD, PhD, professor of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer.
Minimal residual disease (MRD) may be prevalent in clinical trials and discussed at conferences, but it is not really used widely in practice, said C. Ola Landgren, MD, PhD, professor of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer.
Transcript
How broadly is MRD assessment actually being used in practice?
MRD testing at the current time is not as widely used as you hear at all the meetings. You hear about it all the time from all the clinical trials, but in standard of care, from all I know, it’s not really fully in sync with all the clinical trials. I think there are a couple of barriers. One barrier is, for example, if you use flow cytometry—based approaches for MRD, flow cytometry is an open technology that can be done in many very different ways, and most centers that use it don’t unfortunately use it in full agreement with the guidelines of how it should be. So, patients who are tested at some of these centers are really not MRD negative, they are found to be negative, but they really didn’t look through enough number of cells, so the gating was not done in a manner that the guidelines really say.
When it comes to the sequencing-based technologies, which I do think will probably be the future very soon, there are already FDA-cleared assays for this, those technologies are available, but currently only for send out. I think when they become available for local use at the individual centers, I think that will completely change the field. And it could also send out probably to more centers across the country and internationally as well that could also be another way of doing it. So, I think basically access will drive that.
Patients With HFrEF, HFpEF See Different Functional Capacity Benefits With Dapagliflozin
December 7th 2023The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as well as 6-minute walk distance.
Read More
Black Patients With Ulcerative Colitis Less Likely to Undergo IPAA Than White Patients
December 7th 2023Overall, the number of patients discharged from hospitals with an ulcerative colitis diagnosis increased between 2009 and 2018, but the number of patients opting for ileal pouch–anal anastomosis (IPAA) decreased.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Negotiations to extend US global HIV/AIDS relief work are deadlocked; the Biden administration delayed its rule on the proposed menthol cigarette ban until March 2024 after lobbying by civil rights groups; federal agencies have partnered with a digital health company to create an at-home test-to-treat program for flu and COVID-19.
Read More
New Investigation Analyzes Magnetic Resonance Measures of DMD for Disease Progression
December 7th 2023Investigators evaluated longitudinal MRI and spectroscopy outcomes and ambulatory function among 180 patients with Duchenne muscular dystrophy (DMD) to establish the utility and reproducibility of magnetic resonance measures of muscle quality at different disease stages.
Read More